<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Garnish SE</submitter><funding>Department of Health | National Health and Medical Research Council</funding><pagination>6046</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10539340</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Across the globe, 2-3% of humans carry the p.Ser132Pro single nucleotide polymorphism in MLKL, the terminal effector protein of the inflammatory form of programmed cell death, necroptosis. Here we show that this substitution confers a gain in necroptotic function in human cells, with more rapid accumulation of activated MLKL&lt;sup>S132P&lt;/sup> in biological membranes and MLKL&lt;sup>S132P&lt;/sup> overriding pharmacological and endogenous inhibition of MLKL. In mouse cells, the equivalent Mlkl S131P mutation confers a gene dosage dependent reduction in sensitivity to TNF-induced necroptosis in both hematopoietic and non-hematopoietic cells, but enhanced sensitivity to IFN-β induced death in non-hematopoietic cells. In vivo, Mlkl&lt;sup>S131P&lt;/sup> homozygosity reduces the capacity to clear Salmonella </pubmed_abstract><journal>Nature communications</journal><pubmed_title>A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation.</pubmed_title><pmcid>PMC10539340</pmcid><funding_grant_id>1105023</funding_grant_id><funding_grant_id>1107149</funding_grant_id><funding_grant_id>2002965</funding_grant_id><funding_grant_id>1092602</funding_grant_id><funding_grant_id>1142669</funding_grant_id><funding_grant_id>2011584</funding_grant_id><pubmed_authors>Horne CR</pubmed_authors><pubmed_authors>Young SN</pubmed_authors><pubmed_authors>Lawlor KE</pubmed_authors><pubmed_authors>Pearson JS</pubmed_authors><pubmed_authors>Silke J</pubmed_authors><pubmed_authors>Kauppi M</pubmed_authors><pubmed_authors>Meng Y</pubmed_authors><pubmed_authors>Slade CA</pubmed_authors><pubmed_authors>Tovey Crutchfield EC</pubmed_authors><pubmed_authors>Frank D</pubmed_authors><pubmed_authors>Jacobsen AV</pubmed_authors><pubmed_authors>Patel KM</pubmed_authors><pubmed_authors>Martin KR</pubmed_authors><pubmed_authors>Eng VV</pubmed_authors><pubmed_authors>Vinuesa CG</pubmed_authors><pubmed_authors>Doerflinger M</pubmed_authors><pubmed_authors>Hall C</pubmed_authors><pubmed_authors>Garnish SE</pubmed_authors><pubmed_authors>Chiou S</pubmed_authors><pubmed_authors>Ambrose R</pubmed_authors><pubmed_authors>Atkin-Smith GK</pubmed_authors><pubmed_authors>Ng AP</pubmed_authors><pubmed_authors>Samson AL</pubmed_authors><pubmed_authors>Cook M</pubmed_authors><pubmed_authors>Wicks IP</pubmed_authors><pubmed_authors>Athanasopoulos V</pubmed_authors><pubmed_authors>Hildebrand JM</pubmed_authors><pubmed_authors>Murphy JM</pubmed_authors><pubmed_authors>Di Rago L</pubmed_authors><pubmed_authors>Ebert G</pubmed_authors><pubmed_authors>Jackson VE</pubmed_authors></additional><is_claimable>false</is_claimable><name>A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation.</name><description>Across the globe, 2-3% of humans carry the p.Ser132Pro single nucleotide polymorphism in MLKL, the terminal effector protein of the inflammatory form of programmed cell death, necroptosis. Here we show that this substitution confers a gain in necroptotic function in human cells, with more rapid accumulation of activated MLKL&lt;sup>S132P&lt;/sup> in biological membranes and MLKL&lt;sup>S132P&lt;/sup> overriding pharmacological and endogenous inhibition of MLKL. In mouse cells, the equivalent Mlkl S131P mutation confers a gene dosage dependent reduction in sensitivity to TNF-induced necroptosis in both hematopoietic and non-hematopoietic cells, but enhanced sensitivity to IFN-β induced death in non-hematopoietic cells. In vivo, Mlkl&lt;sup>S131P&lt;/sup> homozygosity reduces the capacity to clear Salmonella </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2026-05-29T01:58:13.345Z</modification><creation>2024-12-03T23:39:04.303Z</creation></dates><accession>S-EPMC10539340</accession><cross_references><pubmed>37770424</pubmed><doi>10.1038/s41467-023-41724-6</doi></cross_references></HashMap>